Researchers at the Center for Neuroscience Research at Children’s National Medical Center have discovered that the two major types of signaling pathways activated during brain cell development—the epidermal growth factor receptor pathway and the Notch pathway—operate together to determine how many and which types of brain cells are created during growth and repair in developing and adult brains.
This knowledge may help scientists design new ways to induce the brain to repair itself when these signals are interrupted, and indicate a need for further research to determine whether disruptions of these pathways in early brain development could lead to common neurodevelopmental disorders such as epilepsy, cerebral palsy, autism, Down syndrome, ADHD, and intellectual disabilities.
“By understanding how these cellular signaling pathways operate in the brain, we may be able to develop genetic or molecular approaches that target those signals to facilitate or induce regeneration of the brain from neural stem cells,” said Vittorio Gallo, PhD, director of the Center for Neuroscience Research at Children’s National. “These signaling pathways, normally activated during brain development, work in concert through the cellular microenvironment and through interactions with existing brain cells to determine how many of each type of brain cell are required for proper brain function.”
These findings will be published in the September issue of Nature.
Dr. Gallo and the research team used an approach in a laboratory setting that modified genes involved in the two signaling pathways. This approach induced gain or loss of function, allowing researchers to change the properties of neural stem cells as they developed—including altering the size of the pool of neural stem cells in the brain, the number of viable neural stem cells, and types of brain cells these stem cells ultimately become.
Neural stem cells can develop into all major cell types of the brain. The discovery of the interaction between the two types of cellular signaling pathways is a critical step toward understanding, and potentially impacting, the molecular networks that regulate the cellular microenvironments, or niches, in which these neural stem cells operate.
“Children’s National provides an ideal setting for pursuing this research, because we are able to use a multidisciplinary approach to our studies,” Dr. Gallo said. “Investigators and clinical fellows work together in the labs to tackle important questions that have great clinical importance for children with neurodevelopmental disabilities, and tap resources and expertise at other institutions as well. This environment allows us to translate our findings into the design of specific therapeutic approaches, working together with neuroscientists, child neurologists, neurosurgeons, and neuro-oncologists.”
The research was conducted by Dr. Gallo and Adan Aguirre, PhD, of the Center for Neuroscience Research at Children’s National Medical Center, and Maria E. Rubio, MD, PhD, of the Department of Otolaryngology at the University of Pittsburgh Medical School.
Contact: Jennifer Stinebiser or Paula Darte at 202-476-4500.
Children’s National Medical Center in Washington, DC, has been serving the nation’s children since 1870. Home to Children’s Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National is consistently ranked among the top pediatric hospitals by U.S.News & World Report and the Leapfrog Group. With 283 beds, more than 1,330 nurses, 550 physicians, and seven regional outpatient centers, Children’s National is the only exclusive provider of pediatric care in the Washington metropolitan area. Children’s National has been recognized by the American Nurses Credentialing Center as a Magnet® designated hospital, the highest level of recognition for nursing excellence that a medical center can achieve. For more information, visit www.ChildrensNational.org, receive the latest news from the Children's National press room, or follow us Facebook and Twitter.